NCT01497808View on ClinicalTrials.gov

RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 29, 2011

Primary Completion Date

December 29, 2013

Study Completion Date

October 12, 2015

Conditions
Metastatic Melanoma
Interventions
DRUG

Ipilimumab

RADIATION

Stereotactic Body Radiation Therapy

Trial Locations (1)

19104

Abramson Cancer Center of the Universirty of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT01497808 - RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA | Biotech Hunter | Biotech Hunter